Breaking News, Financial News

Bristol-Myers Squibb

Plavix continued to lead the way, as Abilify revenues slipped and other products showed growth

Bristol-Myers Squibb 2Q10

2Q10 Revenues: $4.8 billion (+2%)

2Q10 Earnings: $927 million (-6%)

YTD Revenues: $9.6 billion (+7%)

YTD Earnings: $1.7 billion (+3%)

Comments: Plavix sales were $1.6 billion for 2Q10 (+6%) and $3.3 billion YTD (+11%). Abilify sales dropped 2% to $633 million in 2Q10 and were up 1% to $1.2 billion YTD. Several products showed strong growth in 2Q10, including Baraclude (+25% in 2Q10 to $223 million), Sprycel (+23% to $132 million), and Orencia (+20% to $178 million). R&D expenditure was flat for the quarter and YTD at $822 million and $1.7 billion, respectively. Onglyza posted $28 million in revenues.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters